📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
IOLCP Receives EDQM CEP Certificate for Metformin Hydrochloride Process-II
IOL Chemicals and Pharmaceuticals Limited (IOLCP) has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & Health Care (EDQM) for its API product, Metformin Hydrochloride Process-II. This certification, granted on March 5, 2026, is an addition to the company's existing valid CEP for Metformin Hydrochloride. Metformin is a widely used antidiabetic drug for managing blood sugar levels. This regulatory milestone strengthens the company's ability to supply this critical API to the European market and other regions that recognize EDQM standards.
Key Highlights
EDQM granted the CEP for Metformin Hydrochloride Process-II on March 5, 2026
The new certification is in addition to the existing valid CEP already held by the company
Metformin Hydrochloride is a key antidiabetic drug used globally for blood sugar management
The approval enhances IOLCP's regulatory compliance and market access in European territories
💼 Action for Investors
Investors should view this as a positive development that reinforces IOLCP's position in the global API market. The additional certification may lead to improved operational flexibility and potential volume growth in the antidiabetic segment.
IOLCP Expands Ethyl Acetate and Acetic Anhydride Capacities via Rs 9.71 Cr Capex
IOL Chemicals and Pharmaceuticals Limited has successfully completed the expansion of its manufacturing facilities for Ethyl Acetate and Acetic Anhydride as of March 2, 2026. The Ethyl Acetate capacity has been increased by 20,000 MTPA to reach 1,20,000 MTPA, while Acetic Anhydride capacity grew by 7,000 MTPA to 32,000 MTPA. The total project cost of Rs 9.71 crore was entirely funded through internal accruals, indicating a healthy balance sheet. This expansion is strategically timed as existing facilities were operating at 90-100% utilization.
Key Highlights
Ethyl Acetate capacity increased from 1,00,000 MTPA to 1,20,000 MTPA (20% increase)
Acetic Anhydride capacity enhanced from 25,000 MTPA to 32,000 MTPA (28% increase)
Total capital expenditure of Rs 9.71 crore funded through internal accruals
Expansion completed on March 2, 2026, to address high utilization rates and market demand
Aims to improve margin realization through optimum operating leverage
💼 Action for Investors
Investors should view this as a positive growth signal as the company is expanding capacity in segments where it already has high utilization. The use of internal accruals for capex further strengthens the investment case by avoiding additional debt.
IOLCP Q3 FY26 Revenue Up 11% to ₹580 Cr; EBITDA Grows 23% with 10.7% Margin
IOL Chemicals and Pharmaceuticals reported a resilient Q3 FY26 with revenue growing 10.9% YoY to ₹580 crores and EBITDA rising 22.8% to ₹62.6 crores. The company's diversification strategy is yielding results, with non-ibuprofen APIs now contributing ₹128 crores to the pharmaceutical segment. Despite persistent high fuel costs in Punjab, management expects a 1-2% margin improvement in Q4 FY26. The board declared a 50% interim dividend, and the company maintains a positive growth guidance of 10-15% for FY27.
Key Highlights
Revenue from operations increased 10.9% YoY to ₹580 crores, while EBITDA grew 22.8% to ₹62.6 crores.
Non-ibuprofen API portfolio contributed ₹128 crores, reflecting successful diversification away from core ibuprofen products.
Capacity utilization remains robust with Ibuprofen at 90-95% and the Chemicals division at nearly 100%.
Management guided for 10-15% top-line and 15-20% bottom-line growth in FY27, supported by ₹150-200 crore annual capex.
Reported a non-recurring exceptional item of ₹11.2 crores pertaining to new labor law provisions.
💼 Action for Investors
Investors should focus on the improving product mix and the ramp-up in paracetamol capacity as key growth drivers. The stock remains a solid play on API diversification and backward integration efficiencies.
IOLCP Declares Rs 1 Interim Dividend; Sets Feb 17 as Record Date for FY 2025-26
IOL Chemicals and Pharmaceuticals Limited (IOLCP) has declared an interim dividend of Rs 1 per equity share, representing 50% of the face value of Rs 2, for the financial year 2025-26. The company has designated February 17, 2026, as the record date to identify eligible shareholders for this payout. Detailed guidelines for Tax Deduction at Source (TDS) have been issued, including a 20% deduction rate for accounts without a valid or linked PAN. Resident individual shareholders are exempt from TDS if their total dividend income from the company does not exceed Rs 10,000 during the fiscal year.
Key Highlights
Interim dividend of Rs 1 per share (50% of face value) declared for FY 2025-26
Record date for dividend entitlement is fixed for February 17, 2026
TDS of 20% applicable for shareholders with invalid or non-Aadhaar linked PAN
Exemption from TDS for resident individuals if total dividend is below Rs 10,000
Deadline for submitting tax exemption forms (15G/15H) is February 17, 2026
💼 Action for Investors
Investors should ensure their PAN is correctly linked and bank details are updated in their demat accounts before the record date. Eligible shareholders should submit Form 15G/15H through the Alankit Assignments portal by February 17 to avoid unnecessary tax deductions.
IOLCP Q3 FY26 Results: EBITDA Grows 22.8% YoY to ₹62.6 Cr; Revenue Up 10.9%
IOL Chemicals and Pharmaceuticals Limited (IOLCP) reported a steady Q3 FY26 performance with revenue growing 10.9% YoY to ₹580.4 Cr. EBITDA margins improved to 10.7% from 9.7% YoY, while PBT before exceptional items surged 39.3% to ₹38.8 Cr. The bottom line was slightly impacted by an exceptional charge of ₹11.2 Cr related to new labour code provisions. The company is successfully diversifying its portfolio, with the non-Ibuprofen segment now contributing significantly to growth.
Key Highlights
Revenue from operations increased 10.9% YoY to ₹580.4 Cr in Q3 FY26.
EBITDA grew 22.8% YoY to ₹62.6 Cr with margins expanding by 100 bps to 10.7%.
PBT before exceptional items rose 39.3% YoY to ₹38.8 Cr.
Commenced New Unit 11 for Paracetamol with a significant installed capacity of 10,800 MTPA.
Maintains a very strong financial position with a Debt-to-Equity ratio of 0.07.
💼 Action for Investors
Investors should focus on the company's successful transition from an Ibuprofen-heavy player to a diversified API manufacturer. The massive expansion in Paracetamol capacity and low leverage provide a strong foundation for long-term growth.
IOLCP Q3 FY26 Results: PBT Jumps 39.3% YoY to ₹38.8 Cr; Pharma Revenue Up 18%
IOL Chemicals and Pharmaceuticals (IOLCP) reported a robust Q3 FY26 performance with revenue growing 10.9% YoY to ₹580.4 crore. Profit Before Tax (before exceptional items) surged by 39.3% YoY to ₹38.8 crore, supported by a 102 bps expansion in EBITDA margins to 10.7%. The growth was largely driven by the Pharmaceuticals segment, which saw an 18% revenue increase and now accounts for 61% of the total revenue mix, up from 57% last year.
Key Highlights
Revenue from operations increased 10.9% YoY to ₹580.4 Cr in Q3 FY26.
PBT (before exceptional items) grew 39.3% YoY to ₹38.8 Cr with a margin of 6.6%.
Pharmaceuticals segment EBIT rose 32% YoY to ₹34.5 Cr, driven by non-Ibuprofen APIs.
Chemicals segment EBIT grew 37% YoY to ₹6.5 Cr despite flat revenue growth.
9M FY26 EBITDA stands at ₹196.1 Cr, up 24.8% compared to the previous year.
💼 Action for Investors
Investors should note the positive shift in product mix towards the higher-margin Pharmaceutical segment and the successful diversification into non-Ibuprofen APIs. The consistent margin expansion over the nine-month period suggests strong operational efficiency and resilience against global headwinds.
IOLCP Reports Q3 Revenue Growth of 11% YoY and Declares ₹1 Interim Dividend
IOL Chemicals and Pharmaceuticals (IOLCP) reported a 10.9% YoY increase in Q3 FY26 revenue to ₹580.39 crore. The company declared an interim dividend of ₹1 per share (50% of face value) with a record date of February 17, 2026. Net profit for the quarter remained flat at ₹20.58 crore, primarily due to an exceptional item of ₹11.21 crore. However, the nine-month performance remains strong with PAT rising 21.8% to ₹84.54 crore compared to the previous year.
Key Highlights
Declared an interim dividend of ₹1 per equity share (50% of FV ₹2) with Record Date as Feb 17, 2026.
Q3 Revenue from operations increased by 10.9% YoY to ₹580.39 crore from ₹523.30 crore.
Nine-month (9M FY26) Net Profit grew by 21.8% to ₹84.54 crore from ₹69.38 crore YoY.
Pharmaceutical segment revenue grew to ₹356.05 crore in Q3, up from ₹300.58 crore in the same quarter last year.
Reported an exceptional item of ₹11.21 crore during the quarter, which impacted the quarterly profit before tax.
💼 Action for Investors
Investors should note the record date of February 17 for dividend eligibility. The steady revenue growth in the pharmaceutical segment is a positive indicator for long-term growth despite the quarterly impact of exceptional items.
IOLCP Q3 Revenue Up 11% YoY to ₹580 Cr; Declares ₹1 Interim Dividend
IOL Chemicals and Pharmaceuticals reported a standalone revenue growth of 11% YoY to ₹580.39 crore for the quarter ended December 2025. While the Pharmaceutical segment saw robust growth in both revenue and profit, the overall Net Profit remained flat at ₹20.58 crore due to an exceptional charge of ₹11.21 crore. On a nine-month basis, the company showed improved performance with PAT rising to ₹84.54 crore from ₹69.38 crore. Additionally, the board rewarded shareholders with an interim dividend of ₹1 per share.
Key Highlights
Revenue from operations increased 11% YoY to ₹580.39 crore in Q3 FY26.
Pharmaceutical segment revenue grew 18.5% YoY to ₹356.05 crore from ₹300.58 crore.
Net Profit for Q3 was ₹20.58 crore, impacted by an exceptional item of ₹11.21 crore.
Interim dividend of ₹1 per share (50%) declared with record date of Feb 17, 2026.
9M FY26 Revenue reached ₹1,699.61 crore compared to ₹1,551.43 crore in the previous year.
💼 Action for Investors
Investors should monitor the nature of the exceptional item and the margin recovery in the chemical segment. The strong performance in the pharmaceutical division is a positive long-term indicator.
IOLCP gets EDQM CEP Certificate for MINOXIDIL
IOL Chemicals and Pharmaceuticals Limited has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & Health Care (EDQM) for its API product "MINOXIDIL" on December 4th, 2025. Minoxidil is used for treating hereditary hair loss. This certification indicates that IOLCP's Minoxidil meets European quality standards, potentially opening up new markets and increasing export opportunities. This regulatory approval can positively impact the company's revenue from API sales.
Key Highlights
EDQM granted CEP Certificate for MINOXIDIL on December 4th, 2025
MINOXIDIL is used as a topical treatment for hereditary hair loss
Certificate issued by the European Directorate for the Quality of Medicines & Health Care (EDQM)
💼 Action for Investors
Investors should monitor IOLCP's sales and revenue growth in the coming quarters to assess the financial impact of this certification. Keep an eye on further regulatory approvals in other geographies.